Skip to main content

Table 1 Clinical characteristics of patients

From: Increased platelet expression of FcGammaRIIa and its potential impact on platelet reactivity in patients with end stage renal disease

Characteristic Low FcγRIIa High FcγRIIa  
  n (%) n (%) p value
Age (mean ± SD) 67 ± 15 67 ± 12 1
male 8 (50%) 10 (63%) 0.87
CAD 11 (71%) 10 (63%) 0.82
CVA/TIA 2 (12%) 7 (44%) 0.15
Hypertension 13 (76%) 16 (100%) 0.55
Diabetes 10 (61%) 10 (63%) 0.89
Hyperlipidemia 11 (65%) 9 (56%) 0.57
Treatment with    
aspirin 9 (53%) 11(69%) 0.89
warfarin 3 (18%) 3 (19%) 0.71
thienopyridine 3 (18%) 5 (31%) 0.64
β blocker 8 (47%) 11 (69%) 0.36
Calcium blocker 7 (41%) 5 (31%) 0.81
ACEI/ARB 7 (41%) 4 (25%) 0.55
insulin 5 (29%) 7 (44%) 0.59
oral hypoglycemic 3 (18%) 3 (19%) 0.71
Duration of HD (mo – mean ± SD) 31 ± 25 32 ± 23 0.91
  1. CAD = coronary arterial disease, CVA = cerebrovascular accident, TIA = transient ischemic attack, ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, HD = hemodialysis, mo = month